HbA1c Testing Device Market By Type of Device (Laboratory-based Testing Devices, Point-of-care Testing Devices) , By Technology (Immunoassays, Chromatography, Enzymatic Assays, Boronate Affinity Chromatography, High-Performance Liquid Chromatography, Others) By End User (Hospitals and Clinics, Diagnostic Laboratories, Homecare Settings) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The HbA1c testing device market was valued at $2.1 billion in 2023, and is projected to reach $3.9 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.
An HbA1c testing device is a medical instrument used to measure glycated hemoglobin (HbA1c) levels in the blood, providing a key indicator of long-term blood glucose control. The test reflects the average blood sugar levels over the past two to three months, making it an essential tool in the management and diagnosis of diabetes. Portable HbA1c testing devices are increasingly popular for point-of-care use, allowing healthcare providers and patients to monitor diabetes more effectively and conveniently.
The growth of the global HbA1c testing device market is majorly driven by alarming increase in the prevalence of diabetes. As per a study published by IDF Diabetes Atlas 10th edition 2021, 537 million individuals were diabetic. This number is estimated to increase to 643 million by 2030 and 783 million by 2045. This highlights the growing demand for diagnostic devices like HbA1c testing to monitor and manage diabetes effectively. In addition, increase in public and healthcare professional awareness of the importance of monitoring long-term blood glucose levels is boosting the adoption of HbA1c tests. Furthermore, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that as the age is the major risk factor for type 2 diabetes. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, rise in focus on individualized treatment plans, particularly for chronic conditions like diabetes, is fostering the demand for regular HbA1c monitoring. However, high cost of devices and testing restrains the market growth. In addition, availability of alternative methods for monitoring diabetes, such as continuous glucose monitoring systems, are becoming increasingly popular due to their real-time glucose tracking abilities, which may reduce demand for HbA1c devices, thus hampering the market growth. On the contrary, improvements in device accuracy, usability, and connectivity, for instance, integration with digital health platforms, are enhancing the appeal of HbA1c testing devices. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global HbA1c testing device market is segmented into type of device, end user, and region. On the basis of type of device, the market is bifurcated into laboratory-based testing devices and point-of-care (POC) testing devices. As per technology, it is segregated into immunoassays, chromatography, enzymatic assays, boronate affinity chromatography, high-performance liquid chromatography, and others. Depending on end user, it is fragmented into hospitals & clinics, diagnostic laboratories, and homecare settings. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key FindingsOn the basis of type of device, the point-of-care testing devices segment is expected to dominate the market from 2024 to 2033.
As per technology, the immunoassays segment is anticipated to exhibit the highest growth during the forecast period.
Depending on end user, the hospitals segment is projected to lead the market in the coming years.
Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the market during the forecast period.
Competition AnalysisCompetitive analysis and profiles of the major players in the global HbA1c testing device market include Abbott Laboratories, Siemens Healthineers AG, Roche Diagnostics, Danaher Corporation (Beckman Coulter), Becton, Dickinson and Company (BD), Thermo Fisher, Mylan N.V, Sysmex Corporation, Menarini Diagnostics, and Bio-Rad Laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Key Market SegmentsBy Type Of DeviceLaboratory-based Testing Devices
Point-of-care Testing Devices
By TechnologyImmunoassays
Chromatography
Enzymatic Assays
Boronate Affinity Chromatography
High-Performance Liquid Chromatography
Others
By End UserHospitals and Clinics
Diagnostic Laboratories
Homecare Settings
By RegionNorth America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market PlayersAbbott Laboratories
Siemens Healthineers AG
Roche Diagnostics
Danaher Corporation (Beckman Coulter)
Becton, Dickinson and Company (BD)
Thermo Fisher
Mylan N.V
Sysmex Corporation
Menarini Diagnostics
Bio-Rad Laboratories